Cipla, SBP Group Sign Exclusive License for HER2 Bispecific ADC Kumar Jeetendra | September 7, 2026 Cipla Limited (BSE: 500087; NSE: CIPLA) (“Cipla”) and Sino Biopharmaceutical Limited (HKEX: 1177) (“SBP Group”) today announced that SBP Group’s subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“CTTQ”), has entered into an exclusive license and supply agreement with Cipla for Rolditamig Deuderuxtecan, also known as TQB2102, a potential best-in-class HER2 bispecific antibody-drug conjugate (“ADC”). …
